CoChat
Sign Up
Cited by 297Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisGenetic Associations and EpidemiologyOccupational and environmental lung diseases

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study

Open access
Allen, Richard J, Porte, Joanne, Braybrooke, Rebecca, Flores, Carlos, Fingerlin, Tasha E, Oldham, Justin M, Guillen-Guio, Beatriz, Ma, Shwu-Fan, Okamoto, Tsukasa, John, Alison E, Obeidat, Ma'en, Yang, Ivana V, Henry, Amanda, Hubbard, Richard B, Navaratnam, Vidya, Saini, Gauri, Thompson, Norma, Booth, Helen L, Hart, Simon P, Hill, Mike R, Hirani, Nik, Maher, Toby M, McAnulty, Robin J, Millar, Ann B, Molyneaux, Philip L, Parfrey, Helen, Rassl, Doris M, Whyte, Moira K B, Fahy, William A, Marshall, Richard P, Oballa, Eunice, Bossé, Yohan, Nickle, David C, Sin, Don D, Timens, Wim, Shrine, Nick, Sayers, Ian, Hall, Ian P, Noth, Imre, Schwartz, David A, Tobin, Martin D, Wain, Louise V, Jenkins, R Gisli·2017·The Lancet Respiratory Medicine
DOI 10.1016/s2213-2600(17)30387-9PMC PMC5666208
Open this paper in CoChat — free accountOpen PDF

Abstract

Background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high mortality, uncertain cause, and few treatment options. Studies have identified a significant genetic risk associated with the development of IPF; however, mechanisms by which genetic risk factors promote IPF remain unclear. We aimed to identify genetic variants associated with IPF susceptibility and provide mechanistic insight using gene and protein expression analyses. Methods We used a two-stage approach: a genome-wide association study in patients with IPF of European ancestry recruited from nine different centres in the UK and controls selected from UK Biobank (stage 1) matched for age, sex, and smoking status; and a follow-up of associated genetic variants in independent datasets of patients with IPF and controls from two independent US samples from the Chicago consortium and the Colorado consortium (stage 2). We investigated the effect of novel signals on gene expression in large transcriptomic and genomic data resources, and examined expression using lung tissue samples from patients with IPF and controls. Findings 602 patients with IPF and 3366 controls were selected for stage 1. For stage 2, 2158 patients with IPF and 5195 controls were selected. We identified a novel genome-wide significant signal of association with IPF susceptibility near A-kinase anchoring protein 13 ( AKAP13 ; rs62025270, odds ratio [OR] 1·27 [95% CI 1·18–1·37], p=1·32 × 10 −9 ) and confirmed previously reported signals, including in mucin 5B ( MUC5B ; rs35705950, OR 2·89 [2·56–3·26], p=1·12 × 10 −66 ) and desmoplakin ( DSP ; rs2076295, OR 1·44 [1·35–1·54], p=7·81 × 10 −28 ). For rs62025270, the allele A associated with increased susceptibility to IPF was also associated with increased expression of AKAP13 mRNA in lung tissue from patients who had lung resection procedures (n=1111). We showed that AKAP13 is expressed in the alveolar epithelium and lymphoid follicles from patients with IPF, and AKAP13 mRNA expression was 1·42-times higher in lung tissue from patients with IPF (n=46) than that in lung tissue from controls (n=51). Interpretation AKAP13 is a Rho guanine nucleotide exchange factor regulating activation of RhoA, which is known to be involved in profibrotic signalling pathways. The identification of AKAP13 as a susceptibility gene for IPF increases the prospect of successfully targeting RhoA pathway inhibitors in patients with IPF. Funding UK Medical Research Council, National Heart, Lung, and Blood Institute of the US National Institutes of Health, Agencia Canaria de Investigación, Innovación y Sociedad de la Información, Spain, UK National Institute for Health Research, and the British Lung Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(17)30387-9

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Quality control and sample selection flow chart (A) Stage 1 genome-wide association study. (B) Stage 2 follow-up analyses. *On identification of a pair of individuals who were second-degree relatives or closer, one individual was excluded. IPF=idiopathic pulmonary fibrosis. †One patient had both call rate <98% and sex mismatch.
Figure 1 Quality control and sample selection flow chart (A) Stage 1 genome-wide association study. (B) Stage 2 follow-up analyses. *On identification of a pair of individuals who were second-degree relatives or closer, one individual was excluded. IPF=idiopathic pulmonary fibrosis. †One patient had both call rate <98% and sex mismatch.CC BY · PubMed Central
Figure 2 Manhattan plot for the discovery genome-wide association study of IPF susceptibility The x axis shows chromosomal position and the y axis shows –log10(p value) from the discovery (stage 1) case-control analysis. Green variants are those that reached genome-wide significance in the meta-analysis of stage 1 and 2 results (and any variant in linkage disequilibrium with the lead variant [r2>0·1]). The blue line shows the threshold used for selecting variants for stage 2 (p=5 × 10−6) and the red line shows genome-wide significance (p=5 × 10−8). Hollow circles show variants showing an association with genotyping array in the controls, and those that did not show an association with IPF in stage 2 (appendix pp 2 and 6). IPF=idiopathic pulmonary fibrosis.
Figure 2 Manhattan plot for the discovery genome-wide association study of IPF susceptibility The x axis shows chromosomal position and the y axis shows –log10(p value) from the discovery (stage 1) case-control analysis. Green variants are those that reached genome-wide significance in the meta-analysis of stage 1 and 2 results (and any variant in linkage disequilibrium with the lead variant [r2>0·1]). The blue line shows the threshold used for selecting variants for stage 2 (p=5 × 10−6) and the red line shows genome-wide significance (p=5 × 10−8). Hollow circles show variants showing an association with genotyping array in the controls, and those that did not show an association with IPF in stage 2 (appendix pp 2 and 6). IPF=idiopathic pulmonary fibrosis.CC BY · PubMed Central
Figure 3 Comparison of case-control association results and lung eQTL results Region plots for a 2 Mb region on chromosome 15 for the stage 1 case-control GWAS (circles above the x axis) and lung eQTL analysis (squares below the x axis). The x axis shows chromosomal position. The y axis above the x-axis shows the –log10(p value) from the case-control analysis and the y axis below the x axis shows the –log10(p value) for AKAP13 expression from the lung eQTL analysis. The blue dotted line shows the significance threshold (p=5 × 10−6) used in stage 1 and the red dotted line shows genome-wide significance (p=5 × 10−8). Boxes at the bottom show gene locations plotted against the same x axis as the case-control and eQTL results, with AKAP13 highlighted in green. Variants are coloured according to linkage disequilibrium with rs62025270 (shown in blue). eQTL=expression quantitative trait locus. GWAS=genome-wide association study.
Figure 3 Comparison of case-control association results and lung eQTL results Region plots for a 2 Mb region on chromosome 15 for the stage 1 case-control GWAS (circles above the x axis) and lung eQTL analysis (squares below the x axis). The x axis shows chromosomal position. The y axis above the x-axis shows the –log10(p value) from the case-control analysis and the y axis below the x axis shows the –log10(p value) for AKAP13 expression from the lung eQTL analysis. The blue dotted line shows the significance threshold (p=5 × 10−6) used in stage 1 and the red dotted line shows genome-wide significance (p=5 × 10−8). Boxes at the bottom show gene locations plotted against the same x axis as the case-control and eQTL results, with AKAP13 highlighted in green. Variants are coloured according to linkage disequilibrium with rs62025270 (shown in blue). eQTL=expression quantitative trait locus. GWAS=genome-wide association study.CC BY · PubMed Central
Figure 4 Lung eQTL results for AKAP13 expression by rs62025270 genotype Three independent datasets are shown. Blue points show normalised residuals of expression of AKAP13 after adjusting for age, sex, and smoking status for each individual by genotype of rs62025270. The box and whiskers show the mean and IQR for each genotype (left-hand y-axis). The grey boxes show the percentage of variance of AKAP13 expression that is explained by rs62025270 (right-hand y-axis). The p value relating the genotype to expression is shown at the top for each sample. Red allele indicates the allele associated with increased IPF susceptibility. eQTL=expression quantitative trait locus.
Figure 4 Lung eQTL results for AKAP13 expression by rs62025270 genotype Three independent datasets are shown. Blue points show normalised residuals of expression of AKAP13 after adjusting for age, sex, and smoking status for each individual by genotype of rs62025270. The box and whiskers show the mean and IQR for each genotype (left-hand y-axis). The grey boxes show the percentage of variance of AKAP13 expression that is explained by rs62025270 (right-hand y-axis). The p value relating the genotype to expression is shown at the top for each sample. Red allele indicates the allele associated with increased IPF susceptibility. eQTL=expression quantitative trait locus.CC BY · PubMed Central
Figure 5 AKAP13 expression in bronchial mucosa and alveolar cells in patients with IPF and controls Sections of lung tissue from controls show AKAP13 expression in the bronchial mucosa (A) and alveolar cells (B). Sections of lung tissue from patients with IPF show low AKAP13 expression in fibroblastic foci (C), and high expression in the epithelium lining fibrotic alveoli (D) and distal small airways (green arrow; E). (F) Strong staining in lymphoid follicles associated with fibrotic regions in patients with IPF. (G) Section of lung tissue from a patient with IPF showing that areas of lung less affected by fibrosis have high numbers of alveolar cells expressing AKAP13 (green arrows). (H) In tissue from regions of the lung unaffected by fibrosis in patients with IPF, type 1 (green arrows) and type 2 (blue arrow) alveolar epithelial cells primarily express AKAP13 in the parenchyma. (I) AKAP13 mRNA expression in whole lung tissue homogenates from patients with IPF and controls. Each point shows a sample from one person and the line shows the mean fold change (black bars show ± SE) in AKAP13 mRNA in 46 patients with IPF and 51 controls. Relative expression (relative to housekeeping gene) is plotted on a log2 scale. AKAP13=A-kinase anchoring protein 13. FF=fibroblastic foci. IPF=idiopathic pulmonary fibrosis. LF=lymphoid follicle.
Figure 5 AKAP13 expression in bronchial mucosa and alveolar cells in patients with IPF and controls Sections of lung tissue from controls show AKAP13 expression in the bronchial mucosa (A) and alveolar cells (B). Sections of lung tissue from patients with IPF show low AKAP13 expression in fibroblastic foci (C), and high expression in the epithelium lining fibrotic alveoli (D) and distal small airways (green arrow; E). (F) Strong staining in lymphoid follicles associated with fibrotic regions in patients with IPF. (G) Section of lung tissue from a patient with IPF showing that areas of lung less affected by fibrosis have high numbers of alveolar cells expressing AKAP13 (green arrows). (H) In tissue from regions of the lung unaffected by fibrosis in patients with IPF, type 1 (green arrows) and type 2 (blue arrow) alveolar epithelial cells primarily express AKAP13 in the parenchyma. (I) AKAP13 mRNA expression in whole lung tissue homogenates from patients with IPF and controls. Each point shows a sample from one person and the line shows the mean fold change (black bars show ± SE) in AKAP13 mRNA in 46 patients with IPF and 51 controls. Relative expression (relative to housekeeping gene) is plotted on a log2 scale. AKAP13=A-kinase anchoring protein 13. FF=fibroblastic foci. IPF=idiopathic pulmonary fibrosis. LF=lymphoid follicle.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 297

Related

See all

Metadata

Authors
Allen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., Guillen-Guio, B., Ma, S.-F., Okamoto, T., John, A. E., Obeidat, M., Yang, I. V., Henry, A., Hubbard, R. B., Navaratnam, V., Saini, G., Thompson, N., Booth, H. L., Hart, S. P., Hill, M. R., Hirani, N., Maher, T. M., McAnulty, R. J., Millar, A. B., Molyneaux, P. L., Parfrey, H., Rassl, D. M., Whyte, M. K. B., Fahy, W. A., Marshall, R. P., Oballa, E., Bossé, Y., Nickle, D. C., Sin, D. D., Timens, W., Shrine, N., Sayers, I., Hall, I. P., Noth, I., Schwartz, D. A., Tobin, M. D., Wain, L. V., & Jenkins, R. G.
Affiliations
  • University of Leicester (GB)
  • University of Nottingham (GB)
  • Universidad de La Laguna (ES)
  • National Jewish Health (US)
  • University of California, Davis (US)
  • University of Chicago (US)
  • University of Colorado Denver (US)
  • University of British Columbia (CA)
  • University College Hospital (GB)
  • Hull York Medical School (GB)
  • University of Oxford (GB)
  • Centre for Inflammation Research (GB)
  • National Institute for Health and Care Research (GB)
  • University College London (GB)
  • University of Bristol (GB)
  • Royal Papworth Hospital (GB)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • University Medical Center Groningen (NL)
Corresponding author
Wain, Louise V
ORCID
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2017-11
Volume
5
Issue
11
Pages
869-880
ISSN
2213-2600 (ISSN-L)
DOI
10.1016/s2213-2600(17)30387-9
PMC
PMC5666208
OpenAlex
W2767079004
Cited by
297
References
54
Citations by year
2026: 21 · 2025: 28 · 2024: 24 · 2023: 39 · 2022: 42 · 2021: 40 · 2020: 45 · 2019: 30 · 2018: 25 · 2017: 2
FWCI
23.07
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Respiratory Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • National Heart, Lung, and Blood Institute (P01 HL092870, R01 HL097163)
  • National Institute for Health and Care Research
  • Medical Research Council Canada (MC_PC_12010)
  • Agencia Canaria de Investigación, Innovación y Sociedad de la Información (CS-2013–13–017, TESIS2015010057)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, genetic susceptibility, AKAP13, MUC5B, DSP, genetic variants, lung gene expression, alveolar epithelium, lymphoid follicles, lung resection, European ancestry, transcriptomics, proteomics, lung proteome
MeSH terms
Tertiary Lymphoid Structures, Aged, Europe, Female, Humans, Male, Middle Aged, Proto-Oncogene Proteins, RNA, Messenger, Genetic Variation, Signal Transduction, Minor Histocompatibility Antigens, Case-Control Studies, Genetic Predisposition to Disease, rhoA GTP-Binding Protein, White People, A Kinase Anchor Proteins, Idiopathic Pulmonary Fibrosis, Genome-Wide Association Study, Alveolar Epithelial Cells, Rho Guanine Nucleotide Exchange Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review